OXYGENTA PHARMACEUTICAL
|
The Current P/E Ratio of OXYGENTA PHARMACEUTICAL is -13.87.
Share Price | ₹56.4 | Oct 13,2025 |
Market Cap | ₹208.6 Cr | |
Earnings-TTM | ₹-15.0 Cr | TTM-Standalone Results |
Price/Earnings | -13.87x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of OXYGENTA PHARMACEUTICAL
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹208.6 Cr] as on Oct 13,2025
(/) Earnings [ ₹-15.0 Cr] based on TTM-Standalone Results
(=) P/E Ratio [ -13.87x ]
Thus, for OXYGENTA PHARMACEUTICAL , the investors are currently willing to pay -13.87 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of OXYGENTA PHARMACEUTICAL !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of OXYGENTA PHARMACEUTICAL over the last five years.
Historical PE (Price/Earnings) ratio chart of OXYGENTA PHARMACEUTICAL
PE Ratio Performance Analysis for OXYGENTA PHARMACEUTICAL
- OXYGENTA PHARMACEUTICAL 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 0.00x.
- OXYGENTA PHARMACEUTICAL 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, OXYGENTA PHARMACEUTICAL 's p/e ratio peaked in Mar2024 at 0x.
- OXYGENTA PHARMACEUTICAL 's p/e ratio hit its five-year low in Mar2024 of 0x.
How does OXYGENTA PHARMACEUTICAL 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
OXYGENTA PHARMACEUTICAL | -15.04 | -13.87 | 208.6 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 10,411.50 | 38.45 | 400,329.0 |
DIVIS LABORATORIES LTD | 2,306.00 | 75.45 | 173,991.0 |
CIPLA LTD | 5,406.81 | 23.36 | 126,326.0 |
TORRENT PHARMACEUTICALS LTD | 2,002.00 | 59.50 | 119,126.0 |
DR REDDYS LABORATORIES LTD | 5,726.70 | 18.39 | 105,324.0 |
MANKIND PHARMA LTD | 1,905.51 | 52.89 | 100,787.0 |
ZYDUS LIFESCIENCES LTD | 4,637.80 | 21.56 | 99,974.4 |
LUPIN LTD | 3,722.18 | 24.18 | 89,997.9 |
AUROBINDO PHARMA LTD | 3,417.93 | 19.32 | 66,022.6 |
ABBOTT INDIA LTD | 1,452.29 | 43.84 | 63,663.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs OXYGENTA PHARMACEUTICAL 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | -13.87x |
Max industry PE | 75.45x |
Median industry PE | 24.18x |
Average industry PE | 33.01x |
You may also like the below Video Courses